文献速递前列腺癌

多西他赛加入前列腺癌一线长期激素治疗(STAMPEDE):模型估算长期生存、质量调整生存与成本效果

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
PubMed 文献 · Eur Urol Oncol · 2018-09-14

基于STAMPEDE试验数据建模评估在英国国家医疗服务体系(NHS)中,为开始长期激素治疗的前列腺癌患者加用多西他赛的成本效果。模型预测多西他赛可延长转移性前列腺癌生存0.89年(质量调整生存0.51年),延长非转移性前列腺癌生存0.78年(质量调整生存0.39年),在转移性前列腺癌中ICER为5514英镑/QALY,在非转移性前列腺癌中QALY更高且成本更低。作者认为多西他赛在英国 setting 下对非转移性和转移性前列腺癌均具有成本效果。

要点

  • 模型预测多西他赛延长转移性前列腺癌生存0.89年,质量调整生存0.51年。
  • 模型预测多西他赛延长非转移性前列腺癌生存0.78年,质量调整生存0.39年。
  • 转移性前列腺癌ICER为5514英镑/QALY,非转移性前列腺癌QALY更高且成本更低。

核心结论

  • 多西他赛在英国 setting 下对非转移性和转移性前列腺癌患者均具有成本效果。
  • 作者认为临床医生应考虑现有证据是否已足够支持在非转移性前列腺癌患者中使用多西他赛。

研究设计与样本

  • 基于STAMPEDE试验数据,在英国NHS setting 下建立模型评估健康结局和成本。
  • STAMPEDE试验纳入开始一线激素治疗的高危、局部晚期、转移性或复发前列腺癌男性。

主要发现

  • 模型预测多西他赛使转移性前列腺癌生存延长0.89年,质量调整生存延长0.51年。
  • 模型预测多西他赛使非转移性前列腺癌生存延长0.78年,质量调整生存延长0.39年。
  • 转移性前列腺癌中多西他赛相较标准治疗的ICER为5514英镑/QALY。
  • 非转移性前列腺癌中多西他赛相较标准治疗QALY更高且成本更低。
  • 在假设无生存优势的模型下,多西他赛在非转移性前列腺癌中仍具有成本效果。

关键数值与推荐

  • 标准治疗为激素治疗≥2年,部分患者接受放疗。
  • 多西他赛剂量75mg/m2,与标准治疗联合,每3周一次,共6个周期。

临床怎么用

  • 作者认为临床医生应考虑现有证据是否已足够支持在非转移性前列腺癌患者中使用多西他赛。
  • 作者指出若等待更成熟的生存数据,部分患者将错过在激素治疗开始时接受多西他赛的机会。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources. OBJECTIVE: To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting. DESIGN, SETTING, AND PARTICIPANTS: We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced metastatic or recurrent PC starting first-line hormone therapy. INTERVENTION: SOC was hormone therapy for ≥2 yr and radiotherapy in some patients. Docetaxel (75mg/m2) was administered alongside SOC for six three-weekly cycles. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The model generated lifetime predictions of costs, changes in survival duration, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). RESULTS AND LIMITATIONS: The model predicted that docetaxel would extend survival (discounted quality-adjusted survival) by 0.89 yr (0.51) for metastatic PC and 0.78 yr (0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER £5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC). Docetaxel remained cost-effective in nonmetastatic PC when the assumption of no survival advantage was modelled. CONCLUSIONS: Docetaxel is cost-effective among patients with nonmetastatic and metastatic PC in a UK setting. Clinicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in patients with nonmetastatic PC, as the opportunity to offer docetaxel at hormone therapy initiation will be missed for some patients by the time more mature survival data are available. PATIENT SUMMARY: Starting docetaxel chemotherapy alongside hormone therapy represents a good use of UK National Health Service resources for patients with prostate cancer that is high risk or has spread to other parts of the body.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Woods BS, Sideris E, Sydes MR, et al. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. Eur Urol Oncol. 2018. PMID: 31158087. doi:10.1016/j.euo.2018.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。